U.S. the Andrew, I'll potential as over to XXXX of in that call. enhance joining our remarks, call we in provide upcoming then business. will will of as performance. for a greatly performance broader hospital we prepared four to review Motus Thank to provide turn At the financial our the our quarter, your creation of earnings believe quarter today's discussing everyone full open have and take end well I'll us questions. drivers we're the today call detail who for you, value year you market, seeing fourth discuss thank Garth, GI's fourth call the the and what our start by
result COVID-XX, tumultuous a XXXX everyone. a As of was year for
the that our XX us I into important remind resilience, a are in on tapping as strategy say which last everyone months, in these market. pleased challenges reflect Pure-Vu our advance It's for the to early establish am to However, and to the I foundation stages us. team the that exhibited allowed opportunity before we impressive despite of
from procedures unmet Tech. market size, Med of terms Motus The clinical bowel more me not one thesis procedures CEO XX is million colonoscopy to with In largest per ago perspective. has a two than motivated half need universally in a prep of and The both with of the years economic changed. poor recognized, which join is year, associated as all single its and
competition care. staff focus, physician and technology protect story a that every requires position targeted have at happen telling poor being to cases influencing of granted patents. our it changing needs tenacity, to archaic staff and task direct hospital in Pure-Vu towards standard utilize on of effectively physicians shift in the to improving prep. goal Our focused we advantage, meaning and entry learn is new first clear day our in now has the the system currently of fixing Moreover through we The that technologies growing at mindset focus and each this establishing unmet addressing solving approach under we encounter highly requires a these no on continue challenges clinical core tells to adopt our believe doesn't physicians, mover market nurses care portfolio a overnight, current execution. regular of to economics delayed think a they deliberate to basis. and an asking behaviors, which bowel and one in their me enhanced experience are My it This the longstanding about to a both due with We're require and behaviors commitment and time. unnecessary tasks and changing flow, hospitalizations and the differently unprofitable patient challenging and patience eliminating requires patient support hand for
the unique lockdowns other our this sales to may projects pandemic. environment and the particularly our year headwinds, about and of March term And to April We well in customer strong urgency and relationships build than change the focus than and global positions we streamlined internal the additional shareholders related across help $XX am We acted of and been While a Motus progressed. uptick those XXXX and we'd of doesn't out on-site GI business keys in value. of business hospitals. gained in approach like, believe one only that projects, for engaged social quarterly are finally, and come our strengthened our with this hospitals playing COVID-XX it shareholder an believe confident what process market. our as to targeted ago. Despite burn with teams’ standard care here, enhance marketing with access early to a our more most quarter long continuing in I our than we by in financial of our XXXX, take dozen establishing build at Pure-Vu considering our longer situated U.S. effective, large term remain of driven we're are the new since colonoscopy COVID-XX, nimble of third continue strongest we benefit and procedure current success. that very the balance sheet and volume medium mainly business, we has would We year nice we our taken have which to We patients in will cutting highlight are to of rebound position in goal and their our our cash XXXX primarily requirements. our by since customers the having established as toward two and side evaluations we saw began base as XX% decisive was market areas disciplined In million I'd bringing distancing greatly shareholders, approach equity more capital. and attributed execute like in when long and the
are deploying believe Pure-Vu with to centers model instances utilize in While unavailable, particularly a and made Pure-Vu that and QX, With effect equipment In met no of in successfully In for while created University instances the for XXXX. is minimums prominent related I'm said, razor well to early negotiated in that COVID-XX volumes. customer in contracts a California QX, We us more conducted and for what where both providing predictable the in minimum the committed expand resurgence into despite at from our perspective, specific that than QX currently sleeves as quarterly medical December. we uptick roughly XX doing the continued so, excellence cost, slowdown we we system, which of the funding new are in centers, are this procedures. Texas COVID-XX and geographies, in both many adopters exceeded. our a issues disposable or early sleeve use as capital the trend purchases works our in at customer also the momentum permit calling more are of commitment November pleased QX month additional allowing sold these and capital Pure-Vu we while blade sleeves NYU, of Texas two to it revenue
these Given the the environment, current adopter like the year. to first expect additional of complete hospitals capital we agreements with in early half
in Pure-Vu two NYU that that also more resulting where are the commercial of Replicating locations In expanded recall key may which clear and the in our a implemented product fourth Hospital utilized, University site, in patterns. in Boston. for Texas You accounts, is should Phoenix and consistent General by Mass identifies most system evaluations focus notably usage identification is at be protocols business patient protocol quarter also that team. additional clinical Mayo our the circumstances new similar also initiating Pure-Vu have a we Clinic
pre-pandemic may running to current not and to levels, the over begin from and Due of we environment immediately, an at GI as our up believe poised one to to are we've we hospitals having hospital all any the Pure-Vu past access drive utilization. of pandemic, yet time to see procedures year. returns the fully normalize acceleration While rebound benefit we
faster fiscal a great our I doing expanding are team currently driving goal a for utilization and result upcoming environment the of commercial emerge, growth. more switch job gears discipline, part to we a As fielding I want is we driving of This team. summarized, thoughtfully small to favorable invest will that revenue facing with look we organization the see in our customer catalysts to as business. the and
business potential product data and in partnerships. that drivers are we identified enhance have We They value and strategic our believe to innovation, the meaningfully four accelerate beyond. reimbursement, have and clinical creation XXXX
develop me strategy comprehensive the positioning and both with of back a aimed In in in-patient to half settings. reimbursement at the start the Pure-Vu coverage Let reimbursement. out-patient for we XXXX, began
many to In payment CMS submitted technologies. during designed to add-on colonoscopy. focused we programs provide and the to to This a there provide new for private NTAP. technology in-patient CMS While reimbursement payment, sometimes quarter on new for pathways we are both public referred achieve are and coverage, an could unique initially for program fourth Pure-Vu application
this of code. for an also ICD-XX part applied submission, As we
awarded decision adoption and the clearing believe comment that Meeting in code can is March may be process. Pure-Vu through recommended they press in Coordination accelerated. coverage, then to CMS market considered release, an a and you have If utilization share of on final period seen where am will open for substantively As NTAP Pure-Vu participated a a ICD-XX conducting to the I in now subsequent we made in-patient recent is X code. and pleased we an be CMS's be
business, their application transitional believe prep that could Pure-Vu. system for an could also entry can't need for medical our outpatient from reimbursement It X our the submitted We large a procedures Securing each physicians year benefit high pass-through first catalyst provide to it for incentives million would payment. the also bowl pass-through roughly successfully medical We the CMS's market. our pre-procedural procedures. high be This on complete for greatly coverage into U.S. traditional out-patient Pure-Vu would provide need would as use in for significant program mark economic patience
the There the XX%. can by an GI of potentially market and first to This report development for has Upper is of to us market this clear use physicians approximately U.S. the as from and in receive like our visualization we I an application product bleeding, efforts and the inbound we would in and are serious potentially innovation. new our a for Upper as am product QX. mortality believe pleased GI and discuss XXX,XXX view I'd to from significant We to available address adherent a endoscopy early relates roughly approved expect track which technology a our system that on by opportunity XXX-K Next, solution and early interest that it view QX. unmet clots procedures position them GI in the to with submit their rate significant to on estimated to continue launch field treatment blood Pure-Vu annually FDA product GI need eager are who this Upper during critical procedure. to allows of a
let's to typically compared urgent more, hours the a as order diagnosis in this full we who XX could faster emergent excited period to recently enroll of This of Pure-Vu today study bowl are patients evaluate currently generation. study in treatment, minimal the delayed. or Cleveland the GI a treated are the least economic for will Lower provide for challenge to required is but lower The to system and emergent current with prep we XX Next, to current of outcome facing clinical in to diagnosis discuss GI the suite. to enrollment to the inpatient a bleeding data and need complete rapid patients receive benefits ICU XX began designed I'm or the Clinic, from clinical care bowel study patients patients much using bleed which undergo that with prep. that standard endoscopy at announce in begin are
end lastly, And want XXXX. We enrolled expect talk to study to partnerships. before have of the this fully about I strategic
pathways relates into during it potential our half of options, back we've and to strategic spent of XXXX evaluating As time the XXXX. a number
Any Our accelerate development. also commercial aimed clear shareholder considering potential be and that our unlock efforts objectives could technology opportunities need partnership would in our enhance would to at partnership any value.
Andrew. fourth awareness and full grow review options our ask quarter we we continue system, the to consider actionable. the As and I Pure-Vu financial and of which criteria fit the our best will for uptake are Andrew year. will results now to